Seroatlas · Human Serome Atlas

ELOA

Elongin-A

Also known as: ELOA1_HUMAN, SIII, TCEB3, TCEB3A

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q14241
Gene
ELOA
Ensembl
ENSG00000011007
Chromosome
1
Canonical length
772 aa
Protein class
Plasma proteins, Predicted intracellular proteins
Subcellular location
Nuclear speckles,Cytosol

OverviewNCBI Gene

This gene encodes the protein elongin A, which is a subunit of the transcription factor B (SIII) complex. The SIII complex is composed of elongins A/A2, B and C. It activates elongation by RNA polymerase II by suppressing transient pausing of the polymerase at many sites within transcription units. Elongin A functions as the transcriptionally active component of the SIII complex, whereas elongins B and C are regulatory subunits. Elongin A2 is specifically expressed in the testis, and capable of forming a stable complex with elongins B and C. The von Hippel-Lindau tumor suppressor protein binds to elongins B and C, and thereby inhibits transcription elongation. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

772 residues, UniProt reviewed canonical sequence.

>Q14241|ELOA
     1  MAAESALQVV EKLQARLAAN PDPKKLLKYL KKLSTLPITV DILAETGVGK TVNSLRKHEH
    61  VGSFARDLVA QWKKLVPVER NAEPDEQDFE KSNSRKRPRD ALQKEEEMEG DYQETWKATG
   121  SRSYSPDHRQ KKHRKLSELE RPHKVSHGHE RRDERKRCHR MSPTYSSDPE SSDYGHVQSP
   181  PSCTSPHQMY VDHYRSLEED QEPIVSHQKP GKGHSNAFQD RLGASQERHL GEPHGKGVVS
   241  QNKEHKSSHK DKRPVDAKSD EKASVVSREK SHKALSKEEN RRPPSGDNAR EKPPSSGVKK
   301  EKDREGSSLK KKCLPPSEAA SDNHLKKPKH RDPEKAKLDK SKQGLDSFDT GKGAGDLLPK
   361  VKEKGSNNLK TPEGKVKTNL DRKSLGSLPK VEETDMEDEF EQPTMSFESY LSYDQPRKKK
   421  KKIVKTSATA LGDKGLKKND SKSTGKNLDS VQKLPKVNKT KSEKPAGADL AKLRKVPDVL
   481  PVLPDLPLPA IQANYRPLPS LELISSFQPK RKAFSSPQEE EEAGFTGRRM NSKMQVYSGS
   541  KCAYLPKMMT LHQQCIRVLK NNIDSIFEVG GVPYSVLEPV LERCTPDQLY RIEEYNHVLI
   601  EETDQLWKVH CHRDFKEERP EEYESWREMY LRLQDAREQR LRVLTKNIQF AHANKPKGRQ
   661  AKMAFVNSVA KPPRDVRRRQ EKFGTGGAAV PEKIKIKPAP YPMGSSHASA SSISFNPSPE
   721  EPAYDGPSTS SAHLAPVVSS TVSYDPRKPT VKKIAPMMAK TIKAFKNRFS RR

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against ELOA can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Intracellular
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.62
Highest tissue expression
34 nTPM

Expression across tissuesHPA

Tissue

  • pancreas: 34 nTPM
  • skeletal muscle: 27 nTPM
  • liver: 25 nTPM
  • parathyroid gland: 23 nTPM
  • tongue: 22 nTPM
  • lung: 20 nTPM

Single-cell type

  • parietal cells: 88 nCPM
  • alveolar cells type 2: 83 nCPM
  • gastric chief cells: 78 nCPM
  • esophageal suprabasal cells: 65 nCPM
  • pancreatic acinar cells: 62 nCPM
  • suprabasal keratinocytes: 59 nCPM

Immune cell

  • basophil: 20 nTPM
  • memory B-cell: 16 nTPM
  • intermediate monocyte: 16 nTPM
  • classical monocyte: 16 nTPM
  • non-classical monocyte: 15 nTPM
  • myeloid DC: 14 nTPM

Brain region

  • cerebellum: 19 nTPM
  • medulla oblongata: 19 nTPM
  • white matter: 18 nTPM
  • thalamus: 18 nTPM
  • midbrain: 17 nTPM
  • choroid plexus: 17 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.12
gnomAD pLI
1
DepMap mean gene effect
-0.17
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of ELOA in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads ELOA as an antibody target. Whether an autoantibody or antibody against ELOA could matter depends on whether native ELOA is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

ELOA is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label ELOA as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/ELOA. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...